Overview of the Hexagon Nutrition Public Offering
Hexagon Nutrition Limited is set to enter the primary market with its Mainboard initial public offering (IPO), scheduled to open for subscription on June 5, 2026, and conclude on June 9, 2026. The company, which provides specialized nutrition products across global markets, plans to raise approximately Rs 138.87 crore through an issue priced between Rs 42 and Rs 45 per share. The shares are expected to debut on the BSE and NSE on June 12, 2026, marking the first major mainboard listing since May.
Understanding the Business Model
Founded in 1993, Hexagon Nutrition operates with a focus on micronutrient premixes, clinical nutrition, and therapeutic foods. The company maintains a diversified manufacturing footprint with three facilities in India and one in Tashkent, Uzbekistan. With a distribution network spanning over 75 countries, Hexagon serves a mix of B2C clinical nutrition consumers, B2B food manufacturers, and institutional partners engaged in social impact nutrition programs.
Financial Performance and Growth Trajectory
The company has demonstrated a consistent upward trend in its financial health over the last three fiscal years. Revenue climbed from Rs 281.65 crore in FY23 to Rs 331.29 crore in FY25, while net profit grew substantially from Rs 5.82 crore to Rs 24.38 crore during the same timeframe. Notably, the momentum has continued into the current fiscal year; for the nine months ending December 2025, the company reported a net profit of Rs 27.03 crore, already surpassing its total earnings for the entire 2025 fiscal year.
Market Positioning and Strategic Metrics
Hexagon Nutrition maintains a conservative capital structure, highlighted by a debt-to-equity ratio of 0.14. While the company operates at a smaller scale than industry giants like Nestlé India or Zydus Wellness, it carves out a specialized niche in the clinical and therapeutic nutrition sectors. Investors should note that the IPO consists of a fresh issue of Rs 27.29 crore alongside an offer for sale, with 50 percent of the issue reserved for Qualified Institutional Buyers (QIBs).
Implications for Investors and Future Outlook
For prospective investors, the IPO represents an entry into a segment that bridges consumer wellness and humanitarian food initiatives. The company’s ability to scale its earnings significantly over the past 24 months suggests strong operational efficiency, though the lack of dividend history indicates a current focus on reinvesting capital for growth. As the June 12 listing date approaches, market participants will be watching the subscription numbers closely to gauge institutional and retail appetite for niche healthcare and nutrition stocks. Future performance will likely depend on the company’s ability to maintain its margin expansion and continue its international distribution expansion strategy.
